Design, Synthesis and Biological Evaluation of Thiazolidine-2,4-dione-biphenyl Derivatives as Anticancer Agents
Related Experiment Video
Updated: May 30, 2025

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
Udaya Sri Earati1, Kiran Gangarapu1, Mahendar Porika2
1School of Pharmacy, Anurag University, Venkatapur(V), Ghatkaser (M), Hyderabad, Telangana, India.
Objective:
A new library of Thiazolidine-2,4-dione-biphenyl Derivatives derivatives (10a-j) was designed and synthesized. All compounds were characterized by spectral data. Further, these were evaluated for their in vitro anticancer activity.
Methods:
The compounds were synthesized as planned in the Scheme-1 and compounds were screened against four human cancer cell lines like cervical cancer (Hela), prostate cancer (PC3), lung cancer cells and breast cancer cells (MDA-MB-231) by employing of MTT assay. Doxorubicin was chosen as positive control.
Result:
Most of the compounds showed moderate to good activity. Among them, these compounds 10b and 10d and displayed more potent activity. Predominantly, one compound 10d showed remarkable anticancer activity. Molecular docking studies with EGFR target (PDB ID: 1M17) exhibits compounds 10b and 10d showed desirable molecular interactions with the same residue similar to cocrystal ligand Erlotinib.
Conclusion:
This results indicate that these two compounds are well targeted the EGFR active sites and showed more inhibitory effects than the other compounds.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Antihypertensive Drugs: Thiazide-Class Diuretics
Inhibition of Cdk Activity
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drug Discovery: Overview

